Axitinib
Brand name: Inlyta
Rank #150 of 500 drugs by total cost
$109.1M
Total Cost
5,937
Total Claims
$109.1M
Total Cost
317
Prescribers
$18K
Cost per Claim
33
Beneficiaries
5,959
30-Day Fills
$344K
Avg Cost/Provider
19
Avg Claims/Provider
About Axitinib
Axitinib (sold as Inlyta) was prescribed 5,937 times by 317 Medicare Part D providers in 2023, costing the program $109.1M. At $18K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 147 | Dimethyl Fumarate (Dimethyl Fumarate) | $109.8M | 29,208 |
| 148 | Immun Glob G(Igg)/Gly/Iga 0-50 (Gammaplex) | $109.6M | 7,815 |
| 149 | Mesalamine (Mesalamine) | $109.3M | 176,079 |
| 150 | Axitinib (Inlyta) | $109.1M | 5,937 |
| 151 | Ipratropium/Albuterol Sulfate (Combivent Respimat) | $108.3M | 353,594 |
| 152 | Relugolix (Orgovyx) | $107.3M | 38,821 |
| 153 | Pen Needle, Diabetic (Ultra-Fine Mini Pen Needle) | $105.0M | 1,305,150 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology